Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of Vagus Nerve Stimulation VNS Therapy as an additional treatment for people with treatment-resistant depression. The study compares active VNS treatment with a no stimulation control over a 12-month period to see if VNS can reduce depressive symptoms measured by several depression scales. This is a prospective, multi-center, randomized, controlled, and blinded trial involving subjects who have VNS devices implanted. Participants receive the VNS implant, and after at least two weeks, they are randomized to either have the device activated or not activated for the first 12 months. Those in the control group can receive stimulation after 12 months. After the initial 12-month randomized phase, all participants transition into an open-label, long-term study lasting about 5 years. New subjects may also enroll directly into this extension phase. During the trial, participants are assessed regularly using multiple depression rating scales and questionnaires to monitor changes in symptoms, response times, remission, and adverse events. Safety and quality of life measures are also tracked. The study includes thorough monitoring of depressive symptoms and overall functioning for up to 12 months post-randomization, followed by long-term observation for several years.
Actively Recruiting
Researchers are studying adults with treatment-resistant depression TRD to evaluate the effects of ALTO-207 compared with a placebo. This clinical trial aims to measure changes in depressive symptoms, particularly focusing on the Montgomery-sberg Depression Rating Scale MADRS scores over eight weeks. The study is randomized, double-blind, and placebo-controlled, conducted by Alto Neuroscience. Participants receive either ALTO-207 or a matching placebo twice daily BID during the treatment phase. The trial follows a parallel design, comparing the effects of the experimental drug to placebo over the course of the study. Throughout the trial, participants undergo assessments including changes in MADRS scores and clinician-administered Clinical Global Impression-Severity CGI-S scores. The primary outcome is the change from baseline in MADRS total score up to eight weeks. Secondary outcomes include response rates and CGI-S score changes. Safety and adherence are monitored, with a total participation period extending through the eight-week treatment phase and follow-up.
Actively Recruiting
Researchers are conducting a randomized trial to study the effects of supervised walking, led by specially trained mobility technicians MTs, on hospitalized medical patients aged 65 and older. The study aims to compare health outcomes and costs between patients receiving this assisted ambulation and those receiving usual care. It also seeks to identify which patients benefit most and assess the financial impact of the intervention over the hospital stay and 30 days afterward. Patients enrolled in the trial will be randomly assigned to either receive usual care or to have mobility technicians help them walk up to three times daily, every day including weekends, during their hospital stay for up to 10 days. The MTs will visit patients multiple times a day to encourage and assist with walking based on individual mobility scores and physical therapy recommendations, if available. All participants will wear wrist accelerometers to track their movement throughout their hospital stay. Participants will be closely monitored with various assessments including the Short Physical Performance Battery SPPB to measure mobility at discharge or after 10 days, and additional follow-ups at 30 days post enrollment to assess physical function, frailty, hospital complications, readmissions, and daily living activities. Researchers will also evaluate total costs related to the hospital stay and 30 days afterward. The study lasts up to 30 days per participant with ongoing safety and outcome monitoring.
Actively Recruiting
Researchers are studying the effects of lumateperone in children and teenagers aged 10 to 17 who have major depressive episodes linked to bipolar I or bipolar II disorder. This is a multicenter, randomized, double-blind study comparing lumateperone to a placebo to understand its potential impact on bipolar depression in pediatric patients. The diagnosis is confirmed using a structured psychiatric interview following DSM-5 criteria. Participants will take either lumateperone or a matching placebo once daily during a 6-week double-blind treatment period. Dosage varies by age, with patients aged 13 to 17 receiving 42 mg and those aged 10 to 12 receiving 21 mg. The study is divided into three phases an initial screening period of up to 2 weeks, the 6-week treatment phase, and a 1-week safety follow-up after the last dose. During the study, participants will undergo assessments including the Childrens Depression Rating Scale-Revised CDRS-R to measure depression severity. Safety will be monitored throughout the trial with a follow-up visit about one week after treatment ends. The study aims to evaluate changes in depressive symptoms over the 6-week treatment, with all visits and assessments scheduled accordingly.
Actively Recruiting
Researchers are evaluating the safety and tolerability of iloperidone, an oral tablet drug, in adolescents aged 12 to 17 years diagnosed with schizophrenia or bipolar I disorder. This study is a phase 4, open-label trial that aims to observe how well patients tolerate iloperidone over a treatment period lasting up to 52 weeks. Participants receive iloperidone in doses ranging from 8 to 24 mg per day throughout the one-year treatment. This is a single-group study without a placebo or comparison group, where all enrolled patients receive the study drug openly. The study focuses on monitoring the occurrence of treatment-emergent adverse events during this period. During the study, participants will be regularly assessed for safety, including monitoring for any adverse events that arise while taking the medication. The main measurement is the number of participants experiencing such events throughout the treatment year. The study is sponsored by Vanda Pharmaceuticals and will continue until the end of 2028, involving adolescents who provide assent along with parental consent.
Actively Recruiting
Researchers are evaluating the safety and tolerability of lumateperone in children and adolescents diagnosed with schizophrenia, bipolar disorder, or autism spectrum disorder. This open-label, multicenter study lasts 26 weeks and aims to better understand how this medication affects pediatric patients with these conditions. The study includes patients who are either new to treatment or rolling over from previous related studies. Participants will receive lumateperone once daily in capsule or orally disintegrating tablet form, with doses ranging from 5 mg to 42 mg based on their age and condition. The trial begins with a screening period up to 2 weeks to confirm eligibility, followed by a 26-week treatment phase where all participants receive open-label lumateperone. After treatment, there is a 2-week safety follow-up visit approximately 2 weeks after the last dose. Throughout the study, participants will attend clinic visits for monitoring and assessments. Researchers will collect safety data, including tracking common adverse events up to six months. Patients must be outpatients expected to remain so during the study. Safety follow-up helps ensure ongoing monitoring after treatment ends, with the entire participation lasting about 28 weeks including screening and follow-up.
Actively Recruiting
Researchers are evaluating the use of the REGENETEN14 Bioinductive Implant system compared to the standard surgical technique called Completion and Repair for treating patients with high-grade partial-thickness rotator cuff tears. The goal is to see if the implant allows patients to return to their daily activities faster and to assess functional recovery at three months after treatment. Participants will undergo surgical repair of their rotator cuff tear using either the REGENETEN Bioinductive Implant Isolated Bioinductive Repair or the standard Completion and Repair method. The study is randomized with two parallel groups comparing these two surgical approaches for partial-thickness tears greater than 50% or 6 mm in size. Throughout the study, participants will be followed up with assessments including shoulder function scores, pain levels, MRI imaging, patient satisfaction, and time to return to work, driving, and sports. These evaluations occur before surgery and at multiple intervals up to 24 months. Researchers will also monitor surgery details, opioid use, physical therapy use, and any revision surgeries, aiming to measure shoulder function improvement primarily at three months after surgery.